Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "lung"

406 News Found

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
Drug Approval | January 07, 2025

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A


Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
Drug Approval | January 02, 2025

Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA

DOVBLERON marks the 13th addition to Innovent’s commercial portfolio


Innovent inks agreement with Roche for Novel DLL3 ADC
News | January 02, 2025

Innovent inks agreement with Roche for Novel DLL3 ADC

Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009


IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors
News | December 31, 2024

IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)


Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
News | December 27, 2024

Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab

Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India


CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
News | December 22, 2024

CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins


Merck to discontinue KeyVibe and Keyform clinical trials
Clinical Trials | December 17, 2024

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program


Briefs: Venus Remedies and GPT Healthcare
News | December 07, 2024

Briefs: Venus Remedies and GPT Healthcare

Venus Remedies secures marketing authorization in Philippines


Merck announces pivotal phase 3 ZENITH trial evaluating WINREVAIR
News | November 26, 2024

Merck announces pivotal phase 3 ZENITH trial evaluating WINREVAIR

WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality


Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
News | November 01, 2024

Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program